title: Effects of pentoxifylline on oxygenation and exercise tolerance in patients with severe chronic obstructive pulmonary disease.
abstract: BACKGROUND
  It was hypothesized that the use of Pentoxifylline would increase arterial O2 saturation and increase exercise tolerance in patients with Chronic Obstructive Pulmonary Disease (COPD).
  
  
  METHODS
  We tested this hypothesis in 23 patients with COPD and pulmonary hypertension. Patients were randomized to receive Pentoxifylline or placebo, each for a 12-week period, in a prospective, double-blind study to assess the effects of Pentoxifylline on oxygen saturation and exercise tolerance via pulse oximetry and the 6-Minute Walk Test (6MWT).
  
  
  RESULTS
  At the end of the 12 weeks, the six-minute walk distance rose from 351.9±65 meters to 393±67 meters in the Pentoxifylline group (10 patients) and increased from 328±79 meters to 353±66 meters in the placebo group (10 patients) (P=0.142). Resting oxygen saturation by pulse oximetry changed from 87±4% to 85±14% in the Pentoxifylline group and from 88±3% to 88±2% in the placebo group (P=0.676). There were no significant changes in dyspnea severity index and heart rate before and after the 6MWT.
  
  
  CONCLUSIONS
  Pentoxifylline does not seem to improve exercise capacity and dyspnea in patients with severe and very severe COPD.
authors.affiliation: Department of Internal Medicine, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran;
authors.forename: Mohammad Javad
authors.initials: MJ
authors.lastname: Fallahi
authors.forename: Seiyed Mohammad Ali
authors.initials: SM
authors.lastname: Ghayumi
authors.forename: Ali Reza
authors.initials: AR
authors.lastname: Moarref
keywords: COPD; Oxygenation; Pentoxifylline
references.citation: Am J Kidney Dis. 2008 Sep;52(3):454-63
references.pmid: 18433957
references.citation: Chest. 1995 Dec;108(6):1562-7
references.pmid: 7497761
references.citation: Can J Physiol Pharmacol. 1988 Apr;66(4):396-401
references.pmid: 3167672
references.citation: J Cardiovasc Pharmacol. 1995;25 Suppl 2:S130-3
references.pmid: 8699852
references.citation: Chest. 1990 Mar;97(3):621-7
references.pmid: 2306966
references.citation: Int J Cancer. 2000 Oct 20;90(5):256-64
references.pmid: 11091349
references.citation: Can J Physiol Pharmacol. 1988 Feb;66(2):146-51
references.pmid: 3370545
references.citation: Am Rev Respir Dis. 1988 May;137(5):1099-103
references.pmid: 3195808
references.citation: J Cardiovasc Pharmacol. 2006 Apr;47(4):571-7
references.pmid: 16680071
references.citation: Pediatr Res. 2000 Jan;47(1):73-8
references.pmid: 10625085
references.citation: Tex Heart Inst J. 1988;15(3):163-5
references.pmid: 15227246
references.citation: Clin Biochem. 1999 Aug;32(6):461-6
references.pmid: 10667482
references.citation: Eur J Clin Pharmacol. 1985;29(1):55-9
references.pmid: 2996906
references.citation: J Appl Physiol (1985). 1989 Jan;66(1):96-101
references.pmid: 2917962
references.citation: Ric Clin Lab. 1986 Oct-Dec;16(4):569-78
references.pmid: 3576055
references.citation: J Med. 1979;10(5):307-29
references.pmid: 393789
references.citation: Adv Exp Med Biol. 1988;222:341-7
references.pmid: 3129913
references.citation: Indian J Pharmacol. 2009 Oct;41(5):213-7
references.pmid: 20177491
references.citation: Int J Chron Obstruct Pulmon Dis. 2010 Apr 07;5:57-71
references.pmid: 20463947
references.citation: Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001733
references.pmid: 17636683
references.citation: Drugs. 2004;64(15):1657-70
references.pmid: 15257627
references.citation: Curr Med Res Opin. 1979;6(4):255-8
references.pmid: 527350